



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/845,992	04/30/2001	Harry R. Howard JR.	PC10434B	2938

7590 06/10/2002

Paul H. Ginsburg
Pfizer Inc.
20th Floor
235 East 42nd Street
New York, NY 10017-5755

EXAMINER

SAEED, KAMAL A

ART UNIT

PAPER NUMBER

1626

DATE MAILED: 06/10/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/845,992	HOWARD ET AL.
Examiner	Art Unit	
Kamal A Saeed	1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-15 is/are pending in the application.

4a) Of the above claim(s) ____ is/are withdrawn from consideration.

5) Claim(s) ____ is/are allowed.

6) Claim(s) ____ is/are rejected.

7) Claim(s) ____ is/are objected to.

8) Claim(s) 1-15 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on ____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

- 1. Certified copies of the priority documents have been received.
- 2. Certified copies of the priority documents have been received in Application No. ____.
- 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). ____ .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____ .	6) <input type="checkbox"/> Other: ____ .

DETAILED ACTION

Claims 1-15 are pending in this application.

Election/Restrictions

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Due to the numerous variables in the claims, e.g. \mathbf{R}^1 , \mathbf{R}^2 , \mathbf{R}^3 , \mathbf{R}^4 , \mathbf{X}_n , \mathbf{Y}_m etc and their widely divergent meanings, a precise listing of inventive groups cannot be made. The following groups are exemplary:

Group I claim(s) 1-6, 9 and 10 drawn in part to compound of the formula I and a pharmaceutical composition of compounds of formula I wherein, **A** and **B** are as defined, \mathbf{R}^1 and \mathbf{R}^2 are selected independently from hydrogen, (C_{1-4}) alkyl, (C_{2-4}) alkenyl and (C_{2-4}) alkynyl \mathbf{R}^3 and \mathbf{R}^4 are as defined and **X**, **Y**, **n** and **m** are as defined and one method of use (e.g. for treating depression).

Group II claim(s) 1-6, 9 and 10 drawn in part to compound of the formula I and a pharmaceutical composition of compounds of formula I wherein, **A** and **B** are as defined, \mathbf{R}^1 and \mathbf{R}^2 are selected independently from hydrogen, (C_{1-4}) alkyl, (C_{2-4}) alkenyl and (C_{2-4}) alkynyl or \mathbf{R}^1 and \mathbf{R}^2 together with the nitrogen to which they are attached form a **five** membered saturated ring containing one or two heteroatoms, wherein the second heteroatom, when present is **nitrogen**, \mathbf{R}^3 and \mathbf{R}^4 are as defined and **X**, **Y**, **n** and **m** are as defined and one method of use (e.g. for treating Parkinson's disease).

Group III claim(s) 1-6, 9 and 10 drawn in part to compound of the formula I and a pharmaceutical composition of compounds of formula I wherein, **A** and **B** are as defined, \mathbf{R}^1 and

\mathbf{R}^2 are selected independently from hydrogen, (C₁₋₄) alkyl, (C₂₋₄) alkenyl and (C₂₋₄) alkynyl or \mathbf{R}^1 and \mathbf{R}^2 together with the nitrogen to which they are attached form a **six** membered saturated ring containing one or two heteroatoms, wherein the second heteroatom, when present is **nitrogen**, \mathbf{R}^3 and \mathbf{R}^4 are as defined and \mathbf{X} , \mathbf{Y} , \mathbf{n} and \mathbf{m} are as defined and one method of use (e.g. for treating Parkinson's disease).


Group IV claim(s) 1-6, 9 and 10 drawn in part to compound of the formula I and a pharmaceutical composition of compounds of formula I wherein, \mathbf{A} and \mathbf{B} are as defined, \mathbf{R}^1 and \mathbf{R}^2 are selected independently from hydrogen, (C₁₋₄) alkyl, (C₂₋₄) alkenyl and (C₂₋₄) alkynyl or \mathbf{R}^1 and \mathbf{R}^2 together with the nitrogen to which they are attached form a **five** membered saturated ring containing one or two heteroatoms, wherein the second heteroatom, when present is oxygen or sulfur, \mathbf{R}^3 and \mathbf{R}^4 are as defined and \mathbf{X} , \mathbf{Y} , \mathbf{n} and \mathbf{m} are as defined and one method of use (e.g. for treating depression).

Group V claim(s) claim(s) 1-6, 9 and 10 drawn in part to compound of the formula I and a pharmaceutical composition of compounds of formula I wherein, \mathbf{A} and \mathbf{B} are as defined, \mathbf{R}^1 and \mathbf{R}^2 are selected independently from hydrogen, (C₁₋₄) alkyl, (C₂₋₄) alkenyl and (C₂₋₄) alkynyl or \mathbf{R}^1 and \mathbf{R}^2 together with the nitrogen to which they are attached form a **six** membered saturated ring containing one or two heteroatoms, wherein the second heteroatom, when present is oxygen or sulfur, \mathbf{R}^3 and \mathbf{R}^4 are as defined and \mathbf{X} , \mathbf{Y} , \mathbf{n} and \mathbf{m} are as defined and one method of use (e.g. for treating Parkinson's disease).

Group VI claim(s) 15 drawn to compound of the formula XVIII wherein, \mathbf{Q} is – C(=O)H, cyano, -C(=O)OH, or -C(=O)NR¹R² wherein \mathbf{R}^1 and \mathbf{R}^2 are selected independently from hydrogen, (C₁₋₄) alkyl or \mathbf{R}^1 and \mathbf{R}^2 together with the nitrogen to which they are attached

form a six membered saturated ring containing one or two heteroatoms, wherein the second heteroatom, when present is oxygen or sulfur, \mathbf{R}^3 and \mathbf{R}^4 and one method of use (e.g. for treating Parkinson's disease).

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Again, this list is not exhausted, as it would be impossible under the time constraints due to the sheer volume of subject matter instantly claimed. Therefore, applicant may choose to elect a single invention by identifying another specific embodiment not listed in the exemplary groups of the invention and examiner will endeavor to group the same. **If applicant is unable to elect a single invention, applicant may instead choose to elect a specific compound and examiner will attempt to group it.** The claims herein lack unity of invention under PCT Rule 13.1 and 13.2 since the compounds defined in the claims lack a significant structural element qualifying as the special technical feature that defines a contribution over the prior art. The compounds claimed contain



, which does not define a contribution over the prior art. The substituents vary extensively and when taken as a whole result in vastly different compounds. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper. Additionally, the vastness of the claimed subject matter and the complications in understanding the claimed subject matter imposes a burden on any examination of the claimed subject matter.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamal Saeed whose telephone number is (703) 308-4592. The examiner can normally be reached on Monday-Friday from 8:00 AM – 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (703) 308 4537. The unofficial fax phone for this group are (703) 308-4556 or 305-3592.


When filing a FAX in Technology Center 1600, please indicate the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communication via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by applicant and should be addressed to [joseph.mckane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-2286.

A facsimile center has been established. The hours of operation are Monday through 8:45AM to 4:45PM. The telecopier numbers for accessing the facsimile machine are (703) 308-4242, (703) 305-3592, and (703) 305-3014.

Kamal Saeed, Ph.D.,
June 5, 2002


Joseph McKane
Supervisory Patent Examiner
Art Unit 1626, Group 1620
Technology Center 1